ProFound Therapeutics is planning to do a major expansion over the course of the next year as it emerges from Flagship Pioneering. The new firm is exploring a wide variety of proteins to enable novel therapeutics in areas like rare disease, immunology and oncology.
The company made its debut on 26 May with $75m in funding from Flagship Pioneering, where it was founded in 2020, built around the in-house ProFoundry platform and the idea that while the Human Genome Project found only 20,000 protein-coding genes, there is
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?